What Wall Street is saying about Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock is presently standing at about $4.30 and lots of equity research firms seem to have a target price set on the stock. The median one-year price target of 8 analysts covering the company is $5.50, which suggests the stock could still rise over 22 percent. The highest analyst price target is $13.00, which implies a rally of -102 percent. And a quick view of analyst notes show that 2 are rating the stock a buy while 3 rate ACHN a strong buy. There are 3 equity research firms advocating a Hold and 0 consider it Sell.
Leerink Partners analysts provided their view on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) recently. The rating firm issued a Outperform rating to this company in a research note released on May 18, 2017. Ladenburg Thalmann analysts disclosed their opinion on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) recently. The rating firm gave a Buy rating to this stock in a research note published on Feb 02, 2017. According to a research note disclosed on Nov 04, 2016, analysts at Chardan Capital Markets have upped their rating on these shares from Sell to Neutral.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Transactions Roundup
Several insiders were part of recent insider activity for the stock. Its Director FISHERMAN JASON S Purchased 50,000 company shares for 39,600, in a transaction on Dec 22. Following the transaction, the Director is left with a stake of 10,000 shares, currently valued at $43,000. Meanwhile, Chief Financial Officer Fenton Mary Kay purchased 2,500 shares worth $10,275, through a transaction dated Dec 05. Following the completion of the transaction, the insider is left with a stake of 2,500 shares, amounting $10,750. ACHN Chief Commercial Officer Truitt Joseph also purchased 3,500 shares, at a stock price of $4.06. This transaction occurred on Dec 02 totals $14,210. After this transaction, the insider’s stake stands at 3,500 shares, with a market value of $15,050.
Executives hold 0.22 percent of the stock. RA CAPITAL MANAGEMENT, LLC is one of the biggest insider owners in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), according to U.S. Securities and Exchange Commission (SEC) filings. The insider owns 13,633,220 shares which have current market value of around $58,622,846.ORBIMED ADVISORS LLC is another major inside shareholder in the company. The insider owns 13,107,200 shares as of 03/31/2017, currently worth $56,360,960. BLACKROCK INC. is ranked as third insider holder of the stock. This insider holds 9,908,372 shares with a market value around $42,606,000 as of recent close.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Earnings Outlook
In Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)’s latest quarter, EPS moved to $-0.15 from $-0.03 in preceding quarter and revenues reached at $0.00M compared to $15.00M. Analysts had expected Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to post net income of about $-0.12 per share on $5.62M in revenue. Looking ahead, analysts on average predict that earnings for the current quarter would come in the range of $-0.20 to $-0.16. That is compared with the $-0.14 in EPS it reported during the same period a year ago.